新里程董事长林杨林解除留置措施 公司上半年净利润同比降逾八成

Core Viewpoint - The chairman of New Mileage, Lin Yanglin, has had his detention measures lifted and is now able to resume his duties, with the company's operations reported to be normal [1][3]. Group 1: Chairman's Status - Lin Yanglin was previously detained by the Taiyuan Municipal Xiaodian District Supervisory Committee for investigation, but the company confirmed that the matter was unrelated to its operations [1][3]. - Following the lifting of the detention, Lin Yanglin is back to fulfilling his responsibilities as chairman, and the company’s production and operational status is reported as normal [3]. - The company had previously indicated that the investigation would not have a significant adverse impact on its operations [3]. Group 2: Financial Performance - In the first half of the year, New Mileage reported a revenue of 1.588 billion yuan, a year-on-year decrease of 20.63%, and a net profit attributable to shareholders of 7.4311 million yuan, down 88.25% year-on-year [5]. - The medical services segment generated 1.38 billion yuan in revenue, while the pharmaceutical segment brought in 210 million yuan [5]. - The gross margin for the medical segment was 26.34%, which increased by 1 percentage point year-on-year, despite a decrease in inpatient visits and average costs due to ongoing adjustments in medical insurance payment policies [5]. - The pharmaceutical segment's gross margin was 40.47%, down 4.69 percentage points, primarily due to a decrease in sales prices following centralized procurement of core products [5]. Group 3: Market Dynamics - New Mileage participated in a national centralized procurement initiative for traditional Chinese medicine, with its product series "Duyiwei" expected to be selected for procurement [6]. - The implementation of centralized procurement faced delays, leading to a significant drop in sales initially, but sales have recently rebounded as confidence in the market has improved [6].